Arthur M. Cohen & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Arthur M. Cohen & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-220	Closed	-$230K	–	144
2024 Q3	$230K	Hold	220	–	–	0.04%	128
2024 Q2	$231K	Hold	220	–	–	0.04%	130
2024 Q1	$212K	Sell	220 -25	-10%	-$23.8K	0.04%	129
2023 Q4	$215K	Hold	245	–	–	0.05%	128
2023 Q3	$202K	Buy	+245	New	+$193K	0.05%	122
2023 Q2	–	Sell	-245	Closed	-$201K	–	142
2023 Q1	$201K	Buy	+245	New	+$185K	0.05%	125

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arthur M. Cohen & Associates's REGN Position: Q4 2024 in Review

Arthur M. Cohen & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 220 shares — an estimated $230K sold.

Arthur M. Cohen & Associates first reported a position in REGN in Q1 2023 and held it in 6 quarters. The position peaked at $231K in Q2 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Arthur M. Cohen & Associates reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Arthur M. Cohen & Associates sold 220 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $230K.
Arthur M. Cohen & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Arthur M. Cohen & Associates's Regeneron Pharmaceuticals position peaked at $231K in Q2 2024.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Arthur M. Cohen & Associates's 13F filing for Q4 2024, filed 15 Jan 2025.